Market Spotlight: Renal Disease
Market Spotlight: Renal Disease
$1,318.00
This Market Spotlight report covers the Renal Disease market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Renal Disease market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, upcoming and regulatory events, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2020, there were approximately 721.1 million prevalent cases of chronic kidney disease (all stages) worldwide. This figure is forecasted to increase to 775.0 million by 2029.
- Datamonitor Healthcare estimates that in 2020, there were 394.9 million cases (54.8%) in stages 1 and 2, 308.0 million cases (42.7%) in stage 3, 12.6 million cases (1.8%) in stage 4, and 5.5 million cases (0.8%) in stage 5.
- The approved drugs in the renal disease space focus on a wide variety of targets. The majority of these therapies are administered via the oral route, with the remainder being intravenous, intramuscular, and subcutaneous formulations.
- The largest proportion of industry-sponsored drugs in active clinical development for renal disease are in Phase II. Therapies in the pipeline for renal disease focus on a wide variety of targets. The majority of these therapies are administered via the oral route.
- High-impact upcoming events for drugs in the renal disease space comprise topline Phase Ib/II, Phase II, Phase IIa, Phase IIb, and Phase III trial results.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for renal disease have been in the early and mid-phases of development, with 55% of trials in Phase I–II, and 45% in Phase III–IV.
- The US has a substantial lead in the number of renal disease clinical trials globally. Germany leads the major European markets, while Japan has the top spot in Asia.
- Clinical trial activity in the renal disease space is dominated by completed trials. AbbVie has the highest number of completed clinical trials for renal disease, with 64 trials.
- AstraZeneca leads industry sponsors with the highest overall number of clinical trials for renal disease, closely followed by AbbVie.
CONTENTS
6 OVERVIEW
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Disease definition
8 Patient segmentation
9 Symptoms
9 Risk factors
9 Diagnosis
11 TREATMENT
11 Treatment of acute kidney injury
11 Treatment of chronic kidney disease
14 EPIDEMIOLOGY
14 Acute kidney injury
14 Chronic kidney disease (CKD)
14 Prevalence methodology
20 MARKETED DRUGS
23 PIPELINE DRUGS
30 RECENT EVENTS AND ANALYST OPINION
30 Jardiance for Chronic Kidney Disease (CKD) (March 16, 2022)
30 Imbarkyd for Chronic Kidney Disease (CKD) (February 28, 2022)
32 ANG-3777 for Acute Kidney Injury (AKI)/Acute Renal Failure (ARF) (December 9, 2021)
33 Imbarkyd for Chronic Kidney Disease (CKD) (December 8, 2021)
37 KEY UPCOMING EVENTS
38 KEY REGULATORY EVENTS
38 Stada Poised To Launch As Calliditas Finally Wins EU Nod For Kinpeygo
38 Calliditas’ Nephrology Gem Tarpeyo Faces EU Regulatory Delay
38 US FDA Turns Down Bardoxolone
39 EU Okay For Kerendia
39 US FDA Formal Dispute Resolution Guides Evolution Of Trials For CKD Complications, Pain
40 No Opinion For Finerenone
40 Nefecon Reverts To Standard Review in EU
41 LICENSING AND ASSET ACQUISITION DEALS
41 Terumo BCT Collaborates With Eliaz Therapeutics For Acute Kidney Injury
41 Roche To Take Ionis Drug Forward Into Crowded Nephropathy Field
41 As Its Debut Cancer Drug Struggles, MorphoSys Continues Refocus With $1bn Licensing Deal
42 CSL Makes $11.7bn Move On Vifor Pharma In Renal Disease Push
42 Chinook And Investor Syndicate Form Joint Venture in China
42 Vifor Bulks Up Renal Franchise With Sanifit And Inositec Acquisitions
43 Everest Partners On BTK Inhibitor With Sinovent, SinoMab
43 Kyowa Kirin Gains Japanese Rights To AM-Pharma’s Ilofotase
43 Vifor Clinches Deal For Travere’s Rare Kidney Disorder Drug
45 REVENUE OPPORTUNITY
46 CLINICAL TRIAL LANDSCAPE
47 Sponsors by status
48 Sponsors by phase
49 Recent events
53 BIBLIOGRAPHY
54 APPENDIX
LIST OF FIGURES
18 Figure 1: Trends in prevalent cases of chronic kidney disease, 2020–29
23 Figure 2: Overview of pipeline drugs for renal disease in the US
23 Figure 3: Pipeline drugs for renal disease, by company
24 Figure 4: Pipeline drugs for renal disease, by drug type
24 Figure 5: Pipeline drugs for renal disease, by classification
32 Figure 6: Imbarkyd for Chronic Kidney Disease (CKD) (February 28, 2022): Phase II – MERLIN Study
33 Figure 7: ANG-3777 for Acute Kidney Injury (AKI)/Acute Renal Failure (ARF) (December 9, 2021): Phase II – Post-Cardiac Surgery AKI Prevention (GUARD)
37 Figure 8: Key upcoming events in renal disease
46 Figure 9: Clinical trials in renal disease
46 Figure 10: Top 10 drugs for clinical trials in renal disease
47 Figure 11: Top 10 companies for clinical trials in renal disease
47 Figure 12: Trial locations in renal disease
48 Figure 13: Renal disease trials status
49 Figure 14: Renal disease trials sponsors, by phase
LIST OF TABLES
16 Table 1: Prevalent cases of chronic kidney disease, 2020–29
19 Table 2: Prevalent cases of chronic kidney disease, by stage, 2020
21 Table 3: Marketed drugs for renal disease
25 Table 4: Pipeline drugs for renal disease in the US
30 Table 5: Jardiance for Chronic Kidney Disease (CKD) (March 16, 2022)
31 Table 6: Imbarkyd for Chronic Kidney Disease (CKD) (February 28, 2022)
32 Table 7: ANG-3777 for Acute Kidney Injury (AKI)/Acute Renal Failure (ARF) (December 9, 2021)
34 Table 8: Imbarkyd for Chronic Kidney Disease (CKD) (December 8, 2021)
45 Table 9: Historical global sales, by drug ($m), 2017–21
45 Table 10: Forecasted global sales, by drug ($m), 2022–26
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Disease Analysis: Bipolar Disorder 
Sign up to the